- Home
- ATNM vs XTKG Comparison
ATNM vs XTKG Comparison
Compare ATNM & XTKG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATNM
- XTKG
- Stock Information
- Founded
- ATNM 2000
- XTKG 1997
- Country
- ATNM United States
- XTKG Singapore
- Employees
- ATNM N/A
- XTKG N/A
- Industry
- ATNM Biotechnology: Pharmaceutical Preparations
- XTKG
- Sector
- ATNM Health Care
- XTKG
- Exchange
- ATNM Nasdaq
- XTKG NYSE
- Market Cap
- ATNM 56.5M
- XTKG 53.6M
- IPO Year
- ATNM N/A
- XTKG 2019
- Fundamental
- Price
- ATNM $1.51
- XTKG $0.13
- Analyst Decision
- ATNM Strong Buy
- XTKG
- Analyst Count
- ATNM 5
- XTKG 0
- Target Price
- ATNM $14.20
- XTKG N/A
- AVG Volume (30 Days)
- ATNM 245.6K
- XTKG 1.7M
- Earning Date
- ATNM 11-26-2024
- XTKG 11-29-2024
- Dividend Yield
- ATNM N/A
- XTKG N/A
- EPS Growth
- ATNM N/A
- XTKG N/A
- EPS
- ATNM N/A
- XTKG N/A
- Revenue
- ATNM $81,000.00
- XTKG $16,824,823.00
- Revenue This Year
- ATNM $186.10
- XTKG N/A
- Revenue Next Year
- ATNM $19,248.94
- XTKG N/A
- P/E Ratio
- ATNM N/A
- XTKG N/A
- Revenue Growth
- ATNM 80.00
- XTKG 60.50
- 52 Week Low
- ATNM $1.33
- XTKG $0.10
- 52 Week High
- ATNM $10.24
- XTKG $1.64
- Technical
- Relative Strength Index (RSI)
- ATNM 36.23
- XTKG 39.08
- Support Level
- ATNM $1.82
- XTKG $0.12
- Resistance Level
- ATNM $1.97
- XTKG $0.16
- Average True Range (ATR)
- ATNM 0.12
- XTKG 0.02
- MACD
- ATNM -0.02
- XTKG 0.00
- Stochastic Oscillator
- ATNM 11.52
- XTKG 50.00
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.
About XTKG X3 HOLDINGS CO LTD
X3 Holdings Co Ltd is company which is responsible for globally providing of Technology Solutions and Services across Diverse Industries that operates across four business segments: digital technologies, renewable energy, Cryptomining Operations, and agriculture technologies.